Male subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale patients of childbearing potential must be willing to use an adequate method of contraception as outlined in Section 6.4.5.3, for the course of the study through 120 days after the last dose of study medication. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.Xx_NEWLINE_xXMale patients of childbearing potential must agree to use an adequate method of contraception as outlined in Section 6.4.5.3, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale participants of childbearing potential must agree to use an adequate method of contraception during the study treatment period and for at least 120 days after the last dose of study treatment.Xx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subject of childbearing potential should have a negative serum pregnancy test performed during the screening period\r\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of reproductive potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; NOTE: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale patient with a partner of childbearing potential agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXCOHORT 1: Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\r\n* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXCOHORT 1: Male subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXCOHORT 2: Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\r\n* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXCOHORT 2: Male subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXIf female of child-bearing potential, is willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.Xx_NEWLINE_xXIf male with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.Xx_NEWLINE_xXMale subjects without a previous vasectomy should agree to use an adequate method of contraception (i.e. abstinence, condom with spermicidal foam/gel/film/cream) starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXParticipants of reproductive potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel or irinotecanXx_NEWLINE_xXFemale participants of non-childbearing potential must be willing to use adequate contraceptive measures from the Screening Visit (Visit 1) through 120 days after the last dose of study drug; male participants must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drugXx_NEWLINE_xXFemale and Male subjects of childbearing potential must be willing to use an adequate method of contraception, starting with the first dose of study drug through 4 weeks after the last dose of study drug. Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXSubject is willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug (male and female participants of childbearing potential)Xx_NEWLINE_xXFemale and male participants of reproductive potential must agree to use contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medicationXx_NEWLINE_xXMale participants must refrain from donating sperm starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medicationXx_NEWLINE_xXMale patients with WOCBP partners and female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 7 months (male participants) or 5 months (female participants) after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale and male subjects of childbearing potential must agree to use an adequate method of contraception, prior to study entry, for the duration of study participation, and 4 months after completion of pembrolizumab administration; contraception is required starting with the first dose of study medication through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale and male subjects of childbearing potential must agree to use an adequate method of contraception; contraception is required prior to study entry and for the duration of study participation and 4 months after completion of pembrolizumab administration; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale and male subjects of childbearing potential must agree to use an adequate method of contraception; contraception is required starting with the first dose of study medication through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXMale participants with partners of must childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXMale participants of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medicationXx_NEWLINE_xXSubjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 26 weeks after the last dose of study therapyXx_NEWLINE_xXIf female of childbearing potential, is willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.Xx_NEWLINE_xXIf male with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.Xx_NEWLINE_xXMale patient with a partner of childbearing potential agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential should be willing to use adequate method of contraception for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year; the two birth control methods can be two barrier methods or a barrier method plus a hormonal method to prevent pregnancy; subjects should start using birth control from the screening visit throughout the study period up to 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with D1 of HiDAC through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose pembrolizumab and 180 days after the last dose of cetuximabXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXFemale participants of childbearing potential must agree to use adequate methods of contraception starting with the first dose of study therapy through 60 days after the last dose of study therapy. \r\n* Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause. \r\n* Note: Abstinence is acceptable if this is the preferred contraception for the participant.Xx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 60 days after the last dose of study therapy. \r\n* Note: Abstinence is acceptable if this is the preferred contraception for the participant.Xx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 180 days after the last dose of study therapyXx_NEWLINE_xXMale and female subjects of child bearing potential must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n*Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n*Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to abstinence or use of an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale and female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; contraception, for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXWomen of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMen of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study treatment.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study treatment through 120 days after the last dose of study treatment.Xx_NEWLINE_xXFemale subjects of childbearing potential must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication (note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject)Xx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication (note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject)Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXAll individuals must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXWilling to use adequate contraception while on the study and until 120 days after the last dose of study drugXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; contraception should be used for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception; contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale patients must agree to use an adequate method of contraception, or to abstain from heterosexual activity (complete abstinence), starting with the first dose of study drug through 7 months after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication.\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.Xx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception for the duration of the study through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale patients of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXBe willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication (male and female subjects of childbearing potentialXx_NEWLINE_xXMale patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 24 weeks (6 months) after the last dose of study therapyXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXIf of childbearing potential as defined in Section 5.7.2, must be willing to use an adequate method of contraception (see Section 5.7.2) from the first dose of study medication through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; contraception, for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception; contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; contraception must be used for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXIf male, agrees to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drugXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception as outlined - contraception, for the course of the study through 120 days after the last dose of study medication. Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception as outlined - contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXSubjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 150 days after the last dose of study therapy (for women of child-bearing potential) or 210 days after the last dose of study therapy (for men who have partners of child-bearing potential)Xx_NEWLINE_xXPOCBP must be willing to use adequate contraception starting with first dose through 120 days after last doseXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception starting with the date of consent through 120 days after the last dose of study medication; NOTE: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the date of consent through 120 days after the last dose of study therapy; NOTE: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXSTUDY TREATMENT: Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use a latex condom during sexual contact with females of childbearing potential even if they have had a successful vasectomy starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an effective method of contraception starting with the first dose of study therapy through the duration of treatmentXx_NEWLINE_xXMale patient with a partner of childbearing potential agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale patients must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drugXx_NEWLINE_xXWilling to use adequate contraception while on the study and until 120 days after the last dose of study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of therapyXx_NEWLINE_xXLYMPHODEPLETION: Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; males must refrain from donating sperm during study participation and for 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale: use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapyXx_NEWLINE_xXMen treated or enrolled on this protocol must agree to use adequate contraception prior to the first dose of study therapy, for the duration of the study participation, and for 120 days after the last dose of study therapyXx_NEWLINE_xXSubjects should agree to use an adequate method of contraception prior to the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Their partners should also be encouraged to use proper method of contraceptionXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study medication until 120 days after the final dose of study medicine; abstinence is acceptable if this is the established and preferred contraceptive method for the subjectXx_NEWLINE_xXMale patients should agree to use an adequate method of contraception starting with the first dose of study therapy through 90 days after the last dose of study therapy, or documented to be surgically sterileXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale patients on treatment with TG02 must agree to use an adequate method of contraception for the duration of the study, and for 30 days after the last dose of study medicationXx_NEWLINE_xXMales must agree to use an adequate method of contraception during the study and for at least 30 days after the last dose of study drug or DasXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; contraception, for the course of the trial through 120 days after the last dose of trial drug; note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject; male subjects of childbearing potential must agree to use an adequate method of contraception; contraception, starting with the first dose of trial therapy through 120 days after the last dose of trial therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale: use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXPatients able to father a child must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* NOTE: Abstinence is acceptable if this is the established and preferred method of contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 31 weeks after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use adequate method of contraception; contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception; contraception, starting with the first dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception during the course of the study and for 30 days after the last dose of the study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.Xx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy and continuing through the last dose of study therapy and for 90 days after the final dose of study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of barrier contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of study medication, throughout the study period, and for up to 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception; contraception, for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception; contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study medication, while on study, through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of last study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 26 weeks after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception during sexual contact with females of childbearing potential starting with the first dose of study drug through 180 days after the last dose of study drugXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; abstinence is considered an acceptable method of contraceptionXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of the study therapyXx_NEWLINE_xXMale participants must agree to use contraception during the treatment period and for at least 120 days after the last dose of pembrolizumab and up to 180 days after last dose of chemotherapeutic agents.Xx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception during the course of the study.Xx_NEWLINE_xXMale patients with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 6 months after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; abstinence is considered an adequate contraception methodXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of radiation therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale patients must agree to use an adequate method of contraception starting with the first dose of NeoVax through 4 weeks after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXPersons of childbearing potential must be willing to use an adequate method of birth control for the course of the study through 120 days after the last dose of study medication\r\n* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred method of contraception for the patientXx_NEWLINE_xXPersons able to father a child must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* NOTE: Abstinence is acceptable if this is the usual lifestyle and preferred method of contraception for the patientXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of MK-3475 through 120 days after the last dose of MK-3475Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use adequate contraception for the course of the study starting with the first dose of study medication through 180 days after the last dose of SOC therapy or 120 days after the last pembrolizumab doseXx_NEWLINE_xXMale participants must agree to use adequate contraception for the course of the study starting with the first dose of study medication through 180 days after the last dose of SOC therapy or 120 days after the last pembrolizumab doseXx_NEWLINE_xXIs willing to use an adequate method of contraception for the course of the study through at least 120 days or longer based on local regulation after the last dose of study drug (male and female participants of childbearing potential).Xx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use adequate contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale participants of childbearing potential must agree to use adequate contraception 28 days prior to study start, continuing throughout the study, and for up to 28 days after the last dose of lenalidomide (or 120 days after the last dose of pembrolizumab).Xx_NEWLINE_xXMale participants of childbearing potential must agree to use adequate contraception from the first dose of study medication, continuing throughout the study, and for up to 28 days after the last dose of lenalidomide (or 120 days after the last dose of pembrolizumab).Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug.Xx_NEWLINE_xXMale participants of childbearing potential should agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medicationXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of pembrolizumab or 180 days after chemotherapy treatment.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab or 180 days after chemotherapy treatment.Xx_NEWLINE_xXFemale participants of childbearing potential and male participants must agree to use adequate contraception 28 days prior to study start and continuing for up to 28 days after the last dose of pomalidomide (or 120 days after the last dose of pembrolizumab)Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study drug.Xx_NEWLINE_xXIf female of childbearing potential, is willing to use adequate contraception for the course of the study through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.Xx_NEWLINE_xXIf male with a female partner(s) of child-bearing potential, must agree to use adequate contraception starting with the first dose of study medication through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents.Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study drug through 120 days after the last dose of study drug.Xx_NEWLINE_xXMale or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 180 days after the last dose of study drugXx_NEWLINE_xXA woman is eligible to participate in the study if she is of Non-childbearing potential, has a negative serum pregnancy test within 7 days of the first dose of study treatment, not lactating, and agrees to use adequate contraception during the study until at least 120 days after the last dose of investigational productXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy \r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use condoms starting with the first dose of study therapy through 30 days after the last dose of study therapy if sexually active with a female of childbearing potentialXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.Xx_NEWLINE_xXFemale and male participants of reproductive potential must agree to use adequate contraception throughout the study period and for up to 120 days after the last dose of study therapy and for up to 180 days after the last dose of chemotherapeutic agents or tyrosine kinase inhibitorsXx_NEWLINE_xXIs willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug (male and female participants of childbearing potential)Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use adequate contraception during the course of the study through 120 days after the last dose of study drugXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study drugXx_NEWLINE_xXMale: use and adequate method of contraception with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale subjects of childbearing potential (FOCBP) must be willing to use an adequate method of contraception; contraception must be used for the course of the study through 120 days after the last dose of study medication\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception; contraception must be used starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: male subjects will be considered to be of non-reproductive potential if they have azoospermia (whether due to having had a vasectomy or due to an underlying medical condition)\r\n* Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy.Xx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception or abstain from heterosexual activity, starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale and male participants of reproductive potential must agree to use adequate contraception starting from the first dose of trial treatment through 90 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale with female partner of childbearing potential agrees to use adequate method of contraception throughout study, until 120 days after last dose of treatment or last blood drawXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use adequate contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXMale participants must agree to use adequate contraception starting with the first dose through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study medication.Xx_NEWLINE_xXMale subjects should agree to use two methods of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel.Xx_NEWLINE_xXMale participants should agree to use an adequate method of birth control starting with the first dose of study therapy through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of study medication through 180 days after the last dose of study medicationXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of the study drug through 120 days after the last dose of the study drugXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of therapyXx_NEWLINE_xXMale participants must be willing to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study treatmentXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants must be willing to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of pembrolizumab or 180 days after the last dose of paclitaxel, docetaxel, or vinflunineXx_NEWLINE_xXMale participants with a female partner(s) of childbearing potential must be willing to use 2 adequate methods of contraception from screening through 120 days after the last dose of pembrolizumabXx_NEWLINE_xXMale participants must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after last dose of pembrolizumab or through 120-180 days after the last dose of docetaxel, methotrexate or cetuximab, acccording to local standard of careXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study medication through 120 days after the last dose of study medicationXx_NEWLINE_xXMale patients must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale and male subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to randomization and be willing to use an adequate method of contraception (e.g. abstinence, intrauterine device, diaphragm with spermicide, etc.) for the course of the study through 120 days after the last dose of study treatment and up to 180 days after last dose of cisplatinXx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception (e.g. abstinence, vasectomy, male condom, etc.) starting with the first dose of study treatment through 120 days after the last dose of study treatment and up to 180 days after last dose of cisplatin, and refrain from donating sperm during this periodXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXFemale and male participants of childbearing potential must be willing to use an adequate method of contraception, starting with the first dose of study treatment through 120 days after the last dose of study treatment and up to 180 days after last dose of chemotherapeutic agentsXx_NEWLINE_xXIf of childbearing potential as defined in Section 5.7.2, must be willing to use an adequate method of contraception (see Section 5.7.2) from the first dose of study medication through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale and male participants of reproductive potential must agree to use adequate contraception during the course of the study through 120 days after study the last dose of study therapyXx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medicationXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemales of childbearing potential and male participants must agree to use adequate contraception starting with the first dose of trial treatment through 90 days after the last dose of study medicationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale patient agrees to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception as outlined for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception as outlined starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; NOTE: abstinence is acceptable if this is the established and preferred contraception for the subjectXx_NEWLINE_xXWomen of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before to study entry and for the duration of study participation; female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours before receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required; female patients of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient; male patients of reproductive potential must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception before the study, for the duration of study participation, and 4 months after completion of MK-3475 (pembrolizumab) and interferon-gamma administrationXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy\r\n* NOTE: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects agree to use an adequate method of contraception starting with the first dose of study therapy through 31 weeks after the last dose of study therapyXx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy.Xx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is greater.Xx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects: unwilling or unable to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days (or longer as specified by local institutional guidelines) after the last dose of study drug.Xx_NEWLINE_xXMale participants of childbearing potential must agree to use an adequate method of contraception starting with the first dose of study drug through 120 days (or longer as specified by local institutional guidelines) after the last dose of study drug.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use adequate method of contraception for the course of the study through 120 days after the last dose of study medication\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXMale participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 120 days (for participants receiving pembrolizumab) or 180 days (for participants receiving BV) after the last dose of study drug.Xx_NEWLINE_xXFemale subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy; Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xXFemale patients of childbearing potential must be willing to use adequate method of contraception - contraception, for the course of the study through 120 days after the last dose of study medication; patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year\r\n* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjectXx_NEWLINE_xXMale patients must agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapyXx_NEWLINE_xX